Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00009958 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00009958: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00009958 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00009958, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
Phase I trial to compare the effectiveness of vaccine therapy with or without sargramostim in treating patients who have solid tumors. Vaccines may make the body build an immune response to kill tumor cells. Combining colony-stimulating factors such as sargramostim with vaccines may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL sargramostim
- BIOLOGICAL recombinant fowlpox-CEA(6D)/TRICOM vaccine
- BIOLOGICAL recombinant vaccinia-CEA(6D)-TRICOM vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2000-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00009958
The ClinicalTrials.gov registry entry for NCT00009958 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00009958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00009958 about?
NCT00009958 is a clinical study titled "Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer". Phase I trial to compare the effectiveness of vaccine therapy with or without sargramostim in treating patients who have solid tumors. Vaccines may make the body build an immune response to kill tumor cells. Combining colony-stimulating factors such as sargramostim with vaccines may kill more tumor ...
What is the current status of trial NCT00009958?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2000-11.
What interventions are being tested in trial NCT00009958?
The interventions under investigation include: laboratory biomarker analysis (OTHER), sargramostim (BIOLOGICAL), recombinant fowlpox-CEA(6D)/TRICOM vaccine (BIOLOGICAL), recombinant vaccinia-CEA(6D)-TRICOM vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00009958?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.